Fosun Pharma subsidiary advances drug clinical trial

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKEX:2196) announced that its subsidiary, Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd., has launched Phase II clinical trials for XH-S004 tablets in China, excluding Hong Kong, Macau, and Taiwan. XH-S004 is a small molecule oral DPP-1 inhibitor developed for the treatment of non-cystic fibrosis bronchiectasis, chronic obstructive pulmonary disease, and other conditions. An additional indication for XH-S004, the treatment of chronic obstructive pulmonary disease, has been approved for clinical trials in China. As of April 2025, the group has invested approximately RMB 61 million in the research and development of XH-S004. The company cautioned that the drug is subject to regulatory approval processes and carries risks inherent in drug development.